Drug intelligence / Profile preview

colistin + meropenem + vancomycin

Development stage: Preclinical
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Intravenous, Inhalation

Overview

A combination antimicrobial therapy consisting of colistin, meropenem, and vancomycin used primarily for treating severe multidrug-resistant infections, particularly those caused by Acinetobacter baumannii. This triple combination leverages synergistic effects, with colistin disrupting the bacterial outer membrane, allowing vancomycin to reach its targets in the cell wall, while meropenem provides additional carbapenem coverage.

Targets

D-Ala-D-Ala (D-Ala-D-Ala terminus)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on colistin + meropenem + vancomycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on colistin + meropenem + vancomycin.

Explore the full profile